Fig. 4

REV7 deficiency reduces TLS efficiency in 5-FU and oxaliplatin resistant CRC cells. a Western blot analysis of REV7 protein expression in HT29 5-Fu-R, REV7 deficient HT29 5-Fu-R clone 1 (HT29 5-Fu-R-KO1), REV7 deficient HT29 5-Fu-R clone 2 (HT29 5-Fu-R-KO2), HT29 5-Fu-R-KO1 with complemented REV7 (HT29 5-Fu-R-KO1 + REV7) and HT29 5-Fu-R-KO2 with complemented REV7 cell lines (HT29 5-Fu-R-KO2 + REV7). b Western blot analysis of REV7 protein expression in HT29 Oxa-R, REV7 deficient HT29 Oxa-R clone 1 (HT29 Oxa-R-KO1), REV7 deficient HT29 Oxa-R clone 2 (HT29 Oxa-R-KO2), HT29 Oxa-R-KO1 with complemented REV7 (HT29 Oxa-R-KO1 + REV7) and HT29 Oxa-R-KO2 with complemented REV7 cell lines (HT29 Oxa-R-KO2 + REV7). c Plasmid-based TLS efficiency analysis in cell lines from Fig. 3a and d Fig. 3b. **p < 0.01; ***p < 0.001 The p-values were calculated by using. Variation is indicated and presented as mean ± SEM